DTIL — Precision Biosciences Share News
0.000.00%
Last trade - 00:00- $183.27m
- $118.15m
- $34.26m
Precision BioSciences Inc expected to post a loss of $1.50 a share - Earnings Preview
Brief: Precision BioSciences Presents New Preclinical Safety Data For PBGENE-HBV Clinical Candidate For Study Of Liver Congress
Precision BioSciences Inc reports results for the quarter ended in March - Earnings Summary
Precision BioSciences Inc expected to post a loss of $1.91 a share - Earnings Preview
Brief: Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Precision BioSciences Inc expected to post a loss of $1.91 a share - Earnings Preview
Brief: Precision Biosciences Announces Return Of Programs And Conclusion Of Collaboration With Prevail Therapeutics
Precision BioSciences Inc reports results for the quarter ended in December - Earnings Summary
Precision BioSciences Inc expected to post a loss of $2.05 a share - Earnings Preview
Brief: Precision Biosciences Inc Expects To Submit A Cta And/Or Ind For Pbgene-Pmm In 2025
Brief: Aquilo Capital Management Reports 9.99% Passive Stake In Precision BioSciences As Of March 1 - SEC Filing
Brief: Perceptive Advisors Llc Reports 7.9% Passive Stake In Precision Biosciences Inc As Of March 5, 2024 - SEC Filing
U.S. STOCKS ON THE MOVE-Silver miners, Albemarle, Pfizer
Precision Bio rises on UK nod to test partner's genetic disorder therapy in humans
Brief: Precision BioSciences Announces MHRA Approval For Partner iECURE To Expand Phase 1/2 Clinical Trial Of ARCUS Gene Editing Program In OTC Deficiency
U.S. STOCKS ON THE MOVE-Madrigal Pharma, Copper miners, NetApp
Precision BioSciences plunges on highly dilutive stock offering
Brief: Precision Biosciences Announces $40.0 Million Offering Of Common Stock And Warrants
Brief: Precision BioSciences Announces Proposed Public Offering Of Common Stock And Warrants